Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Nadal returns to Roland Garros to practice amid doubts over fitness and form
PARIS (AP) — Rafael Nadal returned to Roland Garros on Monday to practice and try and figure out whe2024-05-21Chinese vice premier stresses importance of sci
XI'AN, March 21 (Xinhua) -- Chinese Vice Premier Liu Guozhong has stressed the importance of acceler2024-05-21Policies yield key results in Xiong'an
Key achievements have been made in implementing a package of measures rolled out by central policyma2024-05-21Chengdu beat Zhejiang to go second in CSL
Wei Shihao scored his first goal for Chengdu Rongcheng in a 3-0 victory over Zhejiang FC in the fift2024-05-21- The 'real-life Martha' from Baby Reindeer bombarded Sir Keir Starmer with almost 300 emails, it has2024-05-21
Woman Overcomes Hearing Loss, Aims for PhD
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment